0001213900-23-097043.txt : 20231219
0001213900-23-097043.hdr.sgml : 20231219
20231219180001
ACCESSION NUMBER: 0001213900-23-097043
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231215
FILED AS OF DATE: 20231219
DATE AS OF CHANGE: 20231219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vivo Capital Fund VIII, L.P.
CENTRAL INDEX KEY: 0001618788
ORGANIZATION NAME:
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40353
FILM NUMBER: 231498755
BUSINESS ADDRESS:
STREET 1: 505 HAMILTON AVENUE, SUITE 200
CITY: PALO ALTO
STATE: CA
ZIP: 94301
BUSINESS PHONE: 650 688 0818
MAIL ADDRESS:
STREET 1: 505 HAMILTON AVENUE, SUITE 200
CITY: PALO ALTO
STATE: CA
ZIP: 94301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vivo Capital Surplus Fund VIII, L.P.
CENTRAL INDEX KEY: 0001628048
ORGANIZATION NAME:
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40353
FILM NUMBER: 231498754
BUSINESS ADDRESS:
STREET 1: 505 HAMILTON AVENUE, SUITE 200
CITY: PALO ALTO
STATE: CA
ZIP: 94301
BUSINESS PHONE: 650 688 0818
MAIL ADDRESS:
STREET 1: 505 HAMILTON AVENUE, SUITE 200
CITY: PALO ALTO
STATE: CA
ZIP: 94301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vivo Capital VIII, LLC
CENTRAL INDEX KEY: 0001618789
ORGANIZATION NAME:
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40353
FILM NUMBER: 231498756
BUSINESS ADDRESS:
STREET 1: 192 LYTTON AVENUE
CITY: PALO ALTO
STATE: CA
ZIP: 94301
BUSINESS PHONE: 650 688 0822
MAIL ADDRESS:
STREET 1: 192 LYTTON AVENUE
CITY: PALO ALTO
STATE: CA
ZIP: 94301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IMPEL PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001445499
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 263058238
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0426
BUSINESS ADDRESS:
STREET 1: 201 ELLIOTT AVE. W
STREET 2: SUITE 260
CITY: SEATTLE
STATE: WA
ZIP: 98119
BUSINESS PHONE: 206-568-1466
MAIL ADDRESS:
STREET 1: 201 ELLIOTT AVE. W
STREET 2: SUITE 260
CITY: SEATTLE
STATE: WA
ZIP: 98119
FORMER COMPANY:
FORMER CONFORMED NAME: IMPEL NEUROPHARMA INC
DATE OF NAME CHANGE: 20080917
4
1
ownership.xml
X0508
4
2023-12-15
1
0001445499
IMPEL PHARMACEUTICALS INC
IMPL
0001618789
Vivo Capital VIII, LLC
192 LYTTON AVENUE
PALO ALTO
CA
94301
0
0
1
0
0001618788
Vivo Capital Fund VIII, L.P.
192 LYTTON AVENUE
PALO ALTO
CA
94301
0
0
1
0
0001628048
Vivo Capital Surplus Fund VIII, L.P.
192 LYTTON AVENUE
PALO ALTO
CA
94301
0
0
1
0
0
Common Stock
2023-12-15
4
S
0
87934
0.29
D
2447181
I
By: Vivo Capital Fund VIII, L.P.
Common Stock
2023-12-15
4
S
0
12066
0.29
D
337608
I
By: Vivo Capital Surplus Fund VIII, L.P.
Common Stock
2023-12-18
4
S
0
209029
0.11
D
2238152
I
By: Vivo Capital Fund VIII, L.P.
Common Stock
2023-12-18
4
S
0
28682
0.11
D
308926
I
By: Vivo Capital Surplus Fund VIII, L.P.
Common Stock
2023-12-19
4
S
0
208657
0.08
D
2029495
I
By: Vivo Capital Fund VIII, L.P.
Common Stock
2023-12-19
4
S
0
28632
0.08
D
280294
I
By: Vivo Capital Surplus Fund VIII, L.P.
The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.44 to $0.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4.
The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.30 to $0.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.
The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.10 to $0.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4.
Vivo Capital VIII, LLC, By: /s/ Frank Kung, Managing Member
2023-12-19
Vivo Capital Fund VIII, L.P., By: Vivo Capital VIII, LLC, its General Partner By: /s/ Frank Kung, Managing Member
2023-12-19
Vivo Capital Surplus Fund VIII, L.P. By: Vivo Capital VIII, LLC, its General Partner By: /s/ Frank Kung, Managing Member
2023-12-19